| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.2K | 9.4% |
| Total Income | 1.2K | 9.4% |
| Expenditure | 1.2K | 0.7% |
| PBT | -64.00 | 64.4% |
| Net Profit | -71.00 | 66.5% |
| OPM | 2.65% | 9.95pp |
| NPM | -5.71% | 12.94pp |
| EPS | -0.20 | 66.7% |
Bausch + Lomb Announces Q1 2026 Results, Raises Guidance on Strong Performance
29 Apr 2026 · 29 Apr, 4:37 pm
Summary
Bausch + Lomb Corporation announced robust first-quarter 2026 financial results, with total revenue reaching $1.244 billion, an increase of 9% as reported and 6% on a constant currency basis year-over-year. The company significantly improved its GAAP Net Loss to $71 million from $212 million in the prior year, while Adjusted EBITDA grew to $189 million. This strong performance, particularly in the Pharmaceuticals segment which saw 14% reported revenue growth, led management to raise its full-year 2026 revenue and Adjusted EBITDA guidance, signaling a positive outlook for continued growth and margin expansion. CEO Brent Saunders emphasized the company's commitment to driving sustainable growth, improving operations, and investing in its pipeline.
Key Highlights
- 1
Bausch + Lomb Corporation reported total revenue of $1.244 billion for the first quarter of 2026, marking a 9% increase as reported and 6% on a constant currency basis compared to the first quarter of 2025.
- 2
The company's GAAP Net Loss attributable to Bausch + Lomb Corporation significantly improved to $71 million in Q1 2026, a favorable change of $141 million from a $212 million loss in the prior year period.
- 3
Adjusted EBITDA (non-GAAP) for the first quarter of 2026 increased by $91 million to $189 million, while Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) rose by $74 million to $200 million.
- 4
Pharmaceuticals segment revenue demonstrated strong growth, increasing by 14% as reported to $305 million, or 12% on a constant currency basis, primarily driven by MIEBO® (+33%) and XIIDRA® (+30%).
- 5
Operating income saw a favorable change of $116 million, reaching $33 million for Q1 2026, compared to an operating loss of $83 million in Q1 2025, driven by revenue performance and operating efficiencies.
- 6
The company raised its full-year 2026 revenue guidance to a range of $5.420 billion to $5.520 billion and its Adjusted EBITDA Excluding Acquired IPR&D guidance to $1.010 billion to $1.060 billion, reflecting strong Q1 performance and a positive outlook.
- 7
Key R&D milestones were achieved, including the filing of the LUMIFY NXT™ NDA and the completion of the seeLYRA™ CE submission.
Management Comments
Brent Saunders
We’re doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward.
Informational and educational content only. Not investment advice.